Background There are limited data on the prognostic utility of regadenoson SPECT
myocardial perfusion imaging (MPI) in patients with end-stage renal disease (ESRD) …

Background The prognostic value of regadenoson SPECT myocardial perfusion imaging
(MPI) has not been specifically studied in patients with end-stage renal disease (ESRD) …

Aims Patients with chronic kidney disease (CKD) have worse cardiovascular outcomes. The
prognostic value of the new pharmacological stressor regadenoson (REG) in patients with …

Background We investigated whether integrating heart rate response (HRR) to regadenoson
with myocardial perfusion imaging (MPI) analysis can enhance risk prediction in end-stage …

Patients with chronic kidney disease (CKD) constitute a special population that carries
substantial risks of developing cardiovascular disease and complications of diagnostic and …

Abstract Purpose of Review Patients with end-stage renal disease (ESRD) have an
increased risk of cardiovascular morbidity and mortality. Cardiac risk assessment, though …

Background Blunted heart rate response (HRR) to vasodilator stress agents is associated
with worse outcomes. There are limited data assessing the effect of impaired HRR to …

Regadenoson is a selective A 2A adenosine receptor agonist that has been approved as a
vasodilator stress agent with single-photon emission-computed tomography (SPECT) …

Background Data on the prognostic value of regadenoson SPECT myocardial perfusion
imaging (MPI) is limited and based on small cohorts. Methods and Results We conducted a …

Background Pharmacokinetic studies suggest delayed clearance of Regadenoson (REG), a
new selective A2A receptor agonist in chronic kidney disease (CKD). The safety of REG in …